Piper Sandler Maintains Neutral on Inari Medical, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains a Neutral rating on Inari Medical (NARI) and lowers the price target from $55 to $50.
May 01, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler maintains a Neutral rating on Inari Medical and lowers the price target from $55 to $50.
The reduction in price target by Piper Sandler suggests a less optimistic outlook on Inari Medical's stock value in the short term, potentially leading to a negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100